A new study offering insights into pulmonary fibrosis, entitled “Secreted frizzled related proteins inhibit fibrosis in vitro but appear redundant in vivo” was published in Fibrogenesis &Tissue Repair by Dr. Rik JU Lories’ research group at University Hospitals Leuven in Belgium. In this new research, the authors investigated…
News
During the European Respiratory Society International Congress (ERS) 2014, held in Munich, Germany last month, a pre-specified subgroup analysis from the two replicate Phase III INPULSIS™ trials revealed that treatment with nintedanib retarded the decline in lung function in patients with idiopathic pulmonary fibrosis (IPF). The study’s findings were…
For the first time ever, a new European Patient Charter for patients who suffer from idiopathic pulmonary fibrosis (IPF) was developed by a group of advocates and presented to the European Parliament on September 30, during IPF World Week 2014. Biotechnology company InterMune, which is dedicated to research, development,…
Drug development company Promedior Inc. recently announced the results of its Phase 1B clinical trial of PRM-15 for treating Idiopathic Pulmonary Fibrosis (IPF). Their findings show that structural and functional imaging of IPF patients correlate with data obtained from standard pulmonary tests. The new data could lead to further development of the therapy as an…
Germany-based multinational pharmaceutical company Boehringer Ingelheim has launched a new mobile app and web page self-test as part of its efforts to raise awareness of Idiopathic pulmonary fibrosis (IPF), a chronic, progressive, severely debilitating, and ultimately lethal lung disease for which there are no FDA-approved treatment options in the U.S. Although…
The U.S. Food and Drug Administration (FDA) organized a workshop on pulmonary fibrosis, which took place on September 26th, in collaboration with the Coalition for Pulmonary Fibrosis (CPF), with the purpose of advocating for the disease throughout the country. Four of the eight panelists at the…
This month, Boehringer Ingelheim presented data concerning the use of nintedanib in patients with idiopathic pulmonary fibrosis (IPF) at the European Respiratory Society International Congress. Data covered two identical phase 3 trials: INPULSIS-1 and INPULSIS-2. “These results provide important insight on the effect of nintedanib across the patients studied…
FibroGen Inc. (FibroGen) recently presented complete data from a clinical study involving the experimental drug FG-3019 in patients with idiopathic pulmonary fibrosis (IPF.) A large group of patients treated with FG-3019 showed a decrease in lung fibrosis. The data was presented during the 18th International Colloquium on Lung and Airway Fibrosis (ICLAF) held in…
cinemafestival / Shutterstock.com Being diagnosed with an incurable, progressively debilitating and life-threatening disease is difficult to cope with. It is even more difficult when the disease is idiopathic, or “of unknown cause.” Former Charmed star Rose McGowan lost her father to an idiopathic form…
New findings resulting from a research collaboration between miRagen Therapeutics Inc., a biopharmaceutical company developing innovative microRNA-based therapeutics, and Yale University scientists demonstrate that synthetic microRNA-29 Mimic promiR-29 reversed fibrosis in a mouse model of pulmonary fibrosis. These findings were published in the journal EMBO Molecular Medicine…
